Core Viewpoint - HCM's financial performance shows a significant decline in revenue and net profit, indicating potential challenges ahead for the company [1][2]. Financial Performance - As of December 31, 2024, HCM reported total revenue of $630 million, a decrease of 24.8% year-over-year [1]. - The company's net profit attributable to shareholders was $37.73 million, reflecting a year-over-year decline of 62.56% [1]. Company Overview - HCM is recognized as one of China's first innovative pharmaceutical R&D companies focused on the global market [2]. - Over the past 20 years, the company has developed a comprehensive integrated R&D innovation platform with world-class discovery and development capabilities [2]. - HCM has successfully launched three self-discovered anti-tumor candidate drugs in China, with the first drug also approved in the United States [2]. - The company has established a profitable commercial platform in China for the production, marketing, and distribution of its innovative oncology drugs, prescription drugs, and consumer health products [2]. - HCM is listed on the Nasdaq Global Select Market, Hong Kong Stock Exchange, and AIM market of the London Stock Exchange [2].
和黄医药(US ADR)上涨2.67%，报15.4美元/股，总市值26.86亿美元